The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Open accessAbstract
BACKGROUND: The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial. METHODS: In an open-label, randomized, controlled trial in Durban, South Africa, we assigned 642 patients with both tuberculosis and HIV infection to start antiretroviral therapy either during tuberculosis therapy (in two integrated-therapy groups) or after the completion of such treatment (in one sequential-therapy group). The diagnosis of tuberculosis was based on a positive sputum smear for acid-fast bacilli. Only patients with HIV infection and a CD4+ cell count of less than 500 per cubic millimeter were included. All patients received standard tuberculosis therapy, prophylaxis with trimethoprim-sulfamethoxazole, and a once-daily antiretroviral regimen of didanosine, lamivudine, and efavirenz. The primary end point was death from any cause. RESULTS: This analysis compares data from the sequential-therapy group and the combined integrated-therapy groups up to September 1, 2008, when the data and safety monitoring committee recommended that all patients receive integrated antiretroviral therapy. There was a reduction in the rate of death among the 429 patients in the combined integrated-therapy groups (5.4 deaths per 100 person-years, or 25 deaths), as compared with the 213 patients in the sequential-therapy group (12.1 per 100 person-years, or 27 deaths); a relative reduction of 56% (hazard ratio in the combined integrated-therapy groups, 0.44; 95% confidence interval, 0.25 to 0.79; P=0.003). Mortality was lower in the combined integrated-therapy groups in all CD4+ count strata. Rates of adverse events during follow-up were similar in the two study groups. CONCLUSIONS: The initiation of antiretroviral therapy during tuberculosis therapy significantly improved survival and provides further impetus for the integration of tuberculosis and HIV services. (ClinicalTrials.gov number, NCT00398996.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Interactions among Drugs for HIV and Opportunistic Infections
Piscitelli, S. C., & Gallicano, K. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441307 · Cited by 320
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa
Mukadi, Y. D., Maher, D., & Harries, A. (2001) · AIDS · doi:10.1097/00002030-200101260-00002 · Cited by 311
Manosuthi, W., Chottanapand, S., Thongyen, S., Chaovavanich, A., & Sungkanuparph, S. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000230521.86964.86 · Cited by 258
Manosuthi, W., Kiertiburanakul, S., Phoorisri, T., & D, S. S. M. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.01.002 · Cited by 148
Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
Burman, W. J., Weis, S. E., Vernon, A. A., Khan, A. Q., Benator, D., Jones, B., Silva, C. R. D. E., King, B., Lahart, C., Mangura, B. T., et al. (2007) · PubMed · Cited by 132
Self-citationPulmonary Tuberculosis in AIDS Patients
Fishman, J. E., Lavi, E. S., Narita, M., et al. (2000) · American Journal of Roentgenology · doi:10.2214/ajr.174.1.1740043 · Cited by 120
Velasco, M., Castilla, V., Sanz, J., Gaspar, G., Condés, E., Barros, C., Cervero, M., Torres, R., & Guijarro, C. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819367e7 · Cited by 112
Cited by
Lawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
HIV and Tuberculosis: a Deadly Human Syndemic
Kwan, C. K., & Ernst, J. D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-10 · Cited by 720
Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013911 · Cited by 612
Health in South Africa: changes and challenges since 2009
Mayosi, B. M., Lawn, J. E., van Niekerk, A., Bradshaw, D., Abdool Karim, S. S., & Coovadia, H. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61814-5 · Cited by 555
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
Self-citationAltice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60829-x · Cited by 504
Self-citationIntegration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., Gengiah, T., Gengiah, S., Naidoo, A., Jithoo, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014181 · Cited by 487
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., & Gumbo, T. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit352 · Cited by 444
Suthar, A. B., Lawn, S. D., del Amo, J., Getahun, H., Dye, C., Sculier, D., Sterling, T. R., Chaisson, R. E., Williams, B. G., Harries, A. D., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001270 · Cited by 402
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Vassall, A., van Kampen, S., Sohn, H., Michael, J. S., John, K. R., den Boon, S., Davis, J. L., Whitelaw, A., Nicol, M. P., Gler, M. T., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001120 · Cited by 313
Torok, M. E., Yen, N. T. B., Chau, T. T. H., Mai, N. T. H., Phu, N. H., Mai, P. P., Dung, N. T., Chau, N. V. V., Bang, N. D., Tien, N. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir230 · Cited by 312
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Dheda, K., Gumbo, T., Gandhi, N. R., Murray, M., Theron, G., Udwadia, Z., Migliori, G. B., & Warren, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70031-1 · Cited by 303
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none
Barber, D. L., Andrade, B. B., Sereti, I., & Sher, A. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2712 · Cited by 169
Metadata
- Authors
- Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., Khan, M., Pienaar, J., El-Sadr, W., Friedland, G., & Abdool Karim, Q.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-02-25
- Volume
- 362
- Issue
- 8
- Pages
- 697-706
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2163899436
- Cited by
- 666
- References
- 17
- FWCI
- 63.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.